Completed PHASE1 INTERVENTIONAL 1-arm NCT00144872

LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures

Evaluation of Lamotrigine in Subjects With Absence Seizures

Sponsor: GlaxoSmithKline

Interventions Lamotrigine

Updated 6 times since 2017 Last updated: Sep 27, 2017 Started: Nov 1, 2004 Primary completion: Apr 22, 2006 Completion: Apr 22, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00144872, this PHASE1 trial focuses on Seizure, Absence and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Oct 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Oct 2017 [monthly]

Completed PHASE1

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Buffalo, United States , Chapel Hill, United States , Fort Worth, United States , Germantown, United States , Greenville, United States , Louisville, United States , Loxahatchee Groves, United States , Madison, United States , Melbourne, United States and 12 more locations